WOBURN, Mass.--(BUSINESS WIRE)--Medicinal Genomics (MGC) and Courtagen Life Sciences today announced that, for the second year, Hawaii will play a key role in organizing the upcoming CannMed 2017 Personalized Cannabinoid Medicine Conference to be held at Harvard Medical School in Boston, MA, April 9-11, 2017. The conference director, Doug Kennedy, and online registration services, provided by Pacific Rim Concepts, are both based in Hawaii. The conference will also provide an opportunity for local physicians and businesses participating in the medical cannabis program to advance their education and network with providers from other states.
"Our young industry needs evidence based approaches to formulating products,” said David Cole, Founder of Wailuku-based Maui Grown Therapies. “CannMed is where the therapeutic possibilities of cannabis are illuminated by rigorous science." Cole will be attending the conference in Boston.
The first CannMed Conference last year attracted the leading physicians and researchers in the medical cannabis world, including Dr. Raphael Mechoulam, “The Father of Marijuana Research.” Topics at this year’s conference will include medical applications such as pain, inflammation, neurology, and cancer, as well as safety, genetics, and regulatory topics.
“The CannMed Conference provides a forum to discuss the current state-of-the-art in medical practice and scientific advances with respect to cannabis medicine,” said Doug Kennedy, Conference Director for CannMed and resident of Manoa Valley.
In addition to returning presenters such as, Dr. Mechoulam, Dr. Bonni Goldstein, Medical Director of Canna-Centers, Dr. John Gaitanis, Chief of Pediatric Neurology at Tufts Medical Center, and Dr. Dustin Sulak, Medical Director of Integr8 Health, the conference will feature first-time speakers, including Dr. Michael Dor, Chief Medical Advisor for the Israeli Ministry of Health Medical Cannabis Unit, Dr. Elizabeth Thiele, Director of the Pediatric Epilepsy Program at Massachusetts General Hospital, and Dr. Jeffrey Hergenrather, President of the Society of Cannabis Clinicians.
This year’s conference will include an option for health care professionals to earn continuing medical education credits (CMEs) in association with TheAnswerPage.com. Medical practitioners that choose this registration option will also be able to choose a non-profit organization to receive a donation through the Courtagen Gives Back Program. Early-bird discounts are available until February 21st. For additional details or to register for CannMed 2017, visit http://www.cannmedevents.com/
To learn more, visit Facebook, Twitter, and Instagram. Follow on social media with hashtags #CannMed #CannMed2017
Note to editors: Passes are available for accredited media upon request.
About Medicinal Genomics Corporation
Medicinal Genomics Corporation applies state-of-the-art life science technology to cannabis plant genetics, and was the first company to sequence the cannabis genome. Our products, based on Next Generation DNA Sequencing technology, help growers, dispensaries, and safety testing laboratories characterize and understand the quality of medicinal cannabis. Medicinal Genomics is a wholly owned subsidiary of Courtagen Life Sciences, Inc. For more information, please visit http://www.medicinalgenomics.com/
About Courtagen Life Sciences, Inc.
Courtagen Life Sciences, Inc., located in Woburn, MA, is a CLIA/CAP certified molecular information company focused on the diagnosis of a range of neurological disorders. Courtagen operates a highly sophisticated Next Generation DNA Sequencing, bioinformatics, and clinical interpretation business. Courtagen’s work helps physicians elucidate the linkages between the genotypes and phenotypes of various neurological diseases. For more information, please visit http://www.courtagen.com/
